Mary Ann Liebert: Building Better Bacteriophage to Combat Antibiotic-Resistant Bacteria
November 21, 2019
November 21, 2019
NEW ROCHELLE, New York, Nov. 21 -- Mary Ann Liebert Inc. issued the following news release:
Researchers are pursuing engineered bacteriophage as alternatives to antibiotics to infect and kill multi-drug resistant bacteria. The potential for an innovative synthetic biology approach to enhance phage therapeutics and the role a biofoundry can play in making this approach feasible and effective is discussed in an article in PHAGE: Therapy, Applications, and Research, a new peer-reviewed . . .
Researchers are pursuing engineered bacteriophage as alternatives to antibiotics to infect and kill multi-drug resistant bacteria. The potential for an innovative synthetic biology approach to enhance phage therapeutics and the role a biofoundry can play in making this approach feasible and effective is discussed in an article in PHAGE: Therapy, Applications, and Research, a new peer-reviewed . . .